A PYMNTS Company

US: Sun Pharma settles Modafinil antitrust suit

By  |  November 27, 2018

Sun Pharma, India’s largest drugmaker  entered into settlements with certain plaintiffs in the Modafinil Antitrust Litigation matter pending in the United States District Court for the Eastern District of Pennsylvania.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The company didn’t disclose the quantum of the settlement amount. “The settlements extend to all claims brought by the Direct Purchaser Plaintiffs. The terms of the settlements are confidential,” Sun Pharma said in a statement to stock exchanges.

    A group of direct purchasers sued Cephalon, Mylan, Teva and Ranbaxy Laboratories in 2006 for so-called “pay-for-delay” settlements in which brand-name drug makers pay their generic counterparts to keep drugs off the market.

    Full Content: Money Control
    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.